^
Association details:
| Biomarker: | FGFR overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | rogaratinib (BAY 1163877) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study
Published date:
08/09/2019
Excerpt:
...103 patients with FGFR mRNA-overexpressing tumours [52 patients with urothelial carcinoma, eight patients with HNSCC, 20 patients with NSCLC, and 23 patients with other tumour types] in the dose-expansion phase). In the expansion cohorts, 15 (15%; 95% CI 8·6-23·5) out of 100 evaluable patients achieved an objective response, with responses recorded in all four expansion cohorts (12 in the urothelial carcinoma cohort and one in each of the other three cohorts), and in ten (67%) of 15 FGFR mRNA-overexpressing tumours without apparent FGFR genetic aberration.
DOI:
10.1016/S1470-2045(19)30412-7
Trial ID:
